mocravimod (KRP-203) / Priothera 
Welcome,         Profile    Billing    Logout  
 6 Diseases   2 Trials   2 Trials   62 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mocravimod (KRP-203) / Priothera
MO-TRANS, NCT05429632: Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS
Adult Acute Myeloid Leukemia
11/25
11/25
2021-002864-36: A phase IIb placebo-controlled efficacy and safety study of mocravimod in AML patients undergoing HSCT

Ongoing
2/3
249
Europe
mocravimod, KRP203, 1.0 mg, Capsule, hard
Priothera S.A.S., Priothera SAS, Priothera S.A.S.
Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), Diseases [C] - Immune System Diseases [C20]
 
 
2022-003618-35: A study to determine the best dose, the efficacy, and safety of mocravimod in patients with large B cell lymphoma treated with genetically modified immune cells (CD19 CAR T cells)

Not yet recruiting
1/2
30
Europe
mocravimod, KRP203, Capsule, hard
Priothera S.A.S., Priothera S.A.S.
Patients with large B cell lymphoma treated with a CD19 CAR T therapy, Patients with large B cell lymphoma treated with a CD19 CAR T therapy, Diseases [C] - Cancer [C04]
 
 

Download Options